PRDM15 and neoplasm: In a study carried out by Yu et al., involving 80 patients with LARC receiving neoadjuvant radiotherapy, poor or non-regression (Tumor regression grade (TRG) 3) exhibited PR-domain-containing proteins 15 (PRDM15) overexpression when compared to radioresponsive patients [96].